HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Dep Chapter 11

This article was originally published in The Rose Sheet

Executive Summary

Dep Chapter 11: Effective Nov. 4, Dep will emerge from bankruptcy, following the Wilmington, Del. U.S. Bankruptcy Court acceptance of the company's Chapter 11 reorganization plan Oct. 23. Under the plan, approved by an official committee representing company's unsecured debtors in August, Dep's lender group, led by Los Angeles-based Foothill Capital Corp., will provide long term financing of $62 mil. at an interest rate of 2% in return for an 8.6% stake in the company or 542,488 shares and $150,000 in cash ("The Rose Sheet" Aug. 26, p. 9). The lender group will also receive warrants to purchase an additional 330,050 shares. Dep will reclassify existing stock, giving all common shares equal voting rights. Dep filed for bankruptcy April 1 with total liabilities of $77.3 mil., comprising $62.2 mil. in secured debt and $15.1 mil in unsecured debt, and assets of $84 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel